Intellectual Property Rights of Nanobiotechnology in Trade Related Aspects of Intellectual Property Rights Agreement (TRIPS)
The emergent field of nanobiotechnology is currently very active worldwide with respect to intellectual property rights (IPR), especially patents. With the emergence of any new technology, nanobiotechnology creates opportunities as well as challenges in adapting the patent regime to its particular context. There is some consensus that patenting nanobiotechnology innovations poses problems than other technologies, owing to their multi-disciplinary character, cross-sectoral applications, broad claims as well as difficulties in fulfilling the patentability criteria of novelty, nonobviousness and industrial application. This is aggravated by the lack of a standardized terminology which impedes easy identification of nanobio-patents and also the fact that patent offices may not be well-equipped to handle nanobiotechnology. Some of the other challenges in nanobiotechnology inventions patenting include: blurring of the interface that previously existed between discoveries and inventions, the lack of specific strategies to deal with the academic patents which do not have exploiting solutions, the lack of technical skills and comprehensive knowledge by national patent offices that may compromise the effectiveness of patents rights by issuing overlapping patent claims, the existence of 'patent thickets' on fundamental nanobio-scale materials, tools and processes which are already creating thorny barriers for would-be innovators and providing new opportunities for sweeping monopoly control over animate matter that could mean monopolizing the basic elements that are the building blocks of the entire natural world, bringing a whole new dimension to the notion of life patenting. To the extent that these are 'foundational' patents—that is, seminal breakthrough inventions upon which later innovations are built—researchers in the developing world could be shut out. Researchers in the global South are likely to find that participation in the 'nanobiotech revolution' is highly restricted by patent tollbooths, obliging them to pay royalties and licensing fees to gain access. This paper seeks to examine the challenges which patenting of nanobiotechnology entails for the patent regimes of especially TRIPS Agreement and how these could be addressed. The paper finally arrives at certain recommendations, to help reconcile the need to incentivize innovation in the new technology, with the imperative of ensuring that the public interest is served and access to the patented knowledge is not hindered.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: 2012-06-01
More about this publication?
- Bionanoscience attempts to harness various functions of biological macromolecules and integrate them with engineering for technological applications. It is based on a bottom-up approach and encompasses structural biology, biomacromolecular engineering, material science, and engineering, extending the horizon of material science. The journal aims at publication of (i) Letters (ii) Reviews (3) Concepts (4) Rapid communications (5) Research papers (6) Book reviews (7) Conference announcements in the interface between chemistry, physics, biology, material science, and technology. The use of biological macromolecules as sensors, biomaterials, information storage devices, biomolecular arrays, molecular machines is significantly increasing. The traditional disciplines of chemistry, physics, and biology are overlapping and coalescing with nanoscale science and technology. Currently research in this area is scattered in different journals and this journal seeks to bring them under a single umbrella to ensure highest quality peer-reviewed research for rapid dissemination in areas that are in the forefront of science and technology which is witnessing phenomenal and accelerated growth.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites